Evidence map›Paper›PMID 42747323›Full record

ArticleAntimicrobial agents and chemotherapy2026

Efficacy of quabodepistat alone and in combination with delamanid and bedaquiline against

L E Via, J Sarathy, D M Weiner, T Greenstein, M Zimmerman, A Abdi, J D Fleegle, F Gomez, F Kaya, M K Piazza and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

L E ViaTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy, and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.ORCID 0000-0001-6074-9521
J SarathyCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
D M WeinerTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy, and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.ORCID 0000-0002-4659-7426
T GreensteinDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.
M ZimmermanCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.ORCID 0000-0002-4390-3555
A AbdiTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, Maryland, USA.
J D FleegleTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, Maryland, USA.
F GomezTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, Maryland, USA.
F KayaCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
M K PiazzaTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, Maryland, USA.
A VatthauerTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, Maryland, USA.
B Y SloanTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, Maryland, USA.
K M RepoliTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, Maryland, USA.
A M WalkerTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, Maryland, USA.
M J WoodcockTuberculosis Imaging Program, Division of Intramural Research, NIAID, NIH, Bethesda, Maryland, USA.
O EgbelowoDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
K GausiDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa.
H I M BoshoffTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy, and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.
Y LiuOtsuka Pharmaceutical Development & Commercialization Inc, Rockville, Maryland, USA.
D ChadalavadaComparitive Medicine Branch, Division of Intramural Research, NIAID, NIH, Bethesda, Maryland, USA.
B B AldridgeDepartment of Molecular Biology and Microbiology, Tufts University School of Medicine, Boston, Massachusetts, USA.ORCID 0000-0003-2236-1424
V DartoisCenter for Discovery and Innovation, Hackensack Meridian Health, Nutley, New Jersey, USA.
C E BarryTuberculosis Research Section, Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy, and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland, USA.ORCID 0000-0002-2927-270X

Funding

Lesion-centric optimization of multidrug therapies for tuberculosisR01AI150684 · NIAID · TUFTS UNIVERSITY BOSTON · PI ALDRIDGE, BREE BEARDSLEY, KIRSCHNER, DENISE E · 2020 to 2024
$4.2M
Bill and Melinda Gates Foundation INV-002483Bill and Melinda Gates Foundation INV-010245Bill and Melinda Gates Foundation INV-040485Bill and Melinda Gates Foundation INV-070003National Institute of Allergy and Infectious DiseasesNIAID NIH HHS R01 AI150684NIH HHS R01AI150684
6 · The paper itself

Abstract

Multidrug-resistant tuberculosis (MDR-TB) is challenging. Bedaquiline (B), delamanid (D), and pretomanid (P) are used in combination regimens with other anti-TB drugs for MDR-TB; however, agents with novel mechanisms of action are needed. DprE1 inhibitor quabodepistat (Q) was developed for combination use. In this study, Q alone or in combination with human-equivalent doses of D and/or B was evaluated in a marmoset TB model using

Indexed as

Antitubercular AgentsDiarylquinolinesMycobacterium tuberculosisNitroimidazolesOxazolesAnimalsBacterial LoadCallithrixDisease Models, AnimalDrug Therapy, CombinationFemaleFluorodeoxyglucose F18LungNitro CompoundsPositron Emission Tomography Computed TomographyTuberculosis, Multidrug-ResistantAntitubercular AgentsbedaquilineDiarylquinolinesFluorodeoxyglucose F18Nitro CompoundsNitroimidazolesOPC-67683Oxazolespretomanidantibioticcavitycommon marmosetgranulomaMycobacterium tuberculosisnon-human primateOPC-167832PET/CTquabodepistat

Identifiers

PMID42747323
PMCPMC13688883

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.